Reversible PulpitisPhase 3NCT04365270
Antibacterial Effect and Clinical Performance of Chitosan Modified Glass Ionomer
A Phase 3 study testing Glass Ionomer, Chitosan Low Molecular Weight (20-200 Mpa.S) and Chlorhexidine Diacetate in people with Reversible Pulpitis and Pulpitis, run by Ain Shams University at 1 site in Egypt.
Trial summary
The study is a randomized clinical trial that assesses the clinical success and the antibacterial effect on carious dentine of glass ionomer when modified with Chitosan and/or Titanium dioxide nano particles vs the control group of modification with Chlorhexidine as control when used in primary molars Read more about this study
- Who is it for?
- Ages 4 to 8 yearsHealthy volunteers can take part
- Conditions the study is for
- Reversible Pulpitis, Pulpitis, Caries,Dental
- What is being tested?
- Glass Ionomer, Chitosan Low Molecular Weight (20-200 Mpa.S) and Chlorhexidine Diacetate
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 65 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Jan 2019to 5 Jan 2021
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 8 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- The teeth will be primary molars selected from patients presented to the outpatient clinic that are
- Healthy patients.
- Age: 4-8 years.
- Children having at least one primary molar with only occlusal caries having dentine lesions wide enough for the smallest excavator to enter (Ø=0.9 mm).
Who cannot join
- Teeth with pulp involvement, those suffering from pain, irreversible pulpits or pulp necrosis.
- Children with systemic diseases.
- Patients with history of active para-functional oral habits, xerostomia.
- Patients who will have difficulties in cooperating.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Antimicrobial Activity and Clinical Performance of Chitosan-modified Glass Ionomer: A Randomized Clinical Trial
The study is a randomized clinical trial that assesses the clinical success and the antibacterial effect on carious dentine of glass ionomer when modified with Chitosan and/or Titanium dioxide nano particles vs the control group of modification with Chlorhexidine as control when used in primary molars
Read the detailed description
Participants will be recruited from the acquitted to the clinic of pediatric dentistry department , Faculty of Dentistry of Ain Shams University. random allocation of the participants where indirect pulp capping is indicated so that modified Glass ionomer would be used as the filling material.
partial removal of caries is done then caries sample would be taken and sent for a microbiological evaluation and then, cavity dimensions is recoded, finally placement of the modified glass ionomer in the prepared cavity.
In a total period of 9 months the patients will be followed every 3 months for clinical evaluation and in the final visit the filling would be removed and another bacterial sample would be taken for comparison, then a permanent filling is placed.
- Conditions
- Reversible Pulpitis, Pulpitis, Caries,Dental, Caries Class I, Caries; Dentin, Caries
- Being tested
- Glass Ionomer, Chitosan Low Molecular Weight (20-200 Mpa.S), Chlorhexidine Diacetate, Titanium Dioxide
- Keywords
- Glass ionomer, Chitosan, Titanium dioxide, Titanium dioxide nanoparticles, Chlorhexidine, indirect pulp capping, Alternative restorative technique, stepwise caries excavation, antibacterial restorative, incomplete caries removal, primary molars, early childhood caries
- Medical subject headings
- Pulpitis, Dental Caries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Glass IonomerDrug
Also called Fuji IX
Glass ionomer filling material would be modified accordingly or used as is
Chitosan Low Molecular Weight (20-200 Mpa.S)Drug
Also called Aldrich, cat#448869, lot #STBG9041
deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
Chlorhexidine DiacetateDrug
Also called chlorhexidine acetate
Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
Titanium DioxideDrug
Also called Titanium(IV) oxide
Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), >99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
| Study group | Role | What they receive |
|---|---|---|
| Chitosan Glass ionomer | Experimental | purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan.
will be placed in the prepared cavity over the last layer of caries Receives: Drug: Glass Ionomer; Drug: Chitosan Low Molecular Weight (20-200 Mpa.S) |
| Chitosan/Titanium dioxide nanoparticles Glass ionomer | Experimental | The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid.
The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries Receives: Drug: Glass Ionomer; Drug: Chitosan Low Molecular Weight (20-200 Mpa.S); Drug: Titanium Dioxide |
| Chlorhexidine glass ionomer | Active comparator | Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v Receives: Drug: Glass Ionomer; Drug: Chlorhexidine Diacetate |
| Glass ionomer | Placebo comparator | Stock powder and liquid Fuji IX from GC japan Receives: Drug: Glass Ionomer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Antibacterial
Dentin samples incubated on 2 culture mediums and total bacterial count by counting colony forming units will be counted. Higher number means Less antibacterial effect
Measured: 9 months
Clinical performance
"Modified United States Public Health Service Ryge Criteria" for Direct Clinical Evaluation and rating of Restoration.measuring color match, anatomic contour, marginal integrity, cavosurface marginal discoloration, secondary caries, surface texture, gross fracture.
each outcome will be graded Alpha(A) for the highest score, Bravo(b) for moderate score, and Charlie(C) for the lowest score.
Measured: followup 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2020
- Study start15 Jan 2019
- Primary completion5 Jan 2021
- Study completion5 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Reversible PulpitisStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 65 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Omar Assem Hodhod, British University In Egypt
- Investigators
- Mariem Wassel, Assistant professor, Study chair, Ainshams UniversityNoha Kabil, Professor, Study director, Ainshams universityomar A Hodhod, Dentist, Principal investigator, British University in cairo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04365270
- Sponsor's protocol ID
- FDASU-REC IM 011730
- Status last verified
- Jan 2021
- First submitted
- 6 Dec 2019
- Last updated
- 12 Jan 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mulder R, Anderson-Small C. Ion release of chitosan and nanodiamond modified glass ionomer restorative cements. Clin Cosmet Investig Dent. 2019 Sep 6;11:313-320. doi: 10.2147/CCIDE.S220089. eCollection 2019.
PubMed 31686917Wassel MO, Khattab MA. Antibacterial activity against Streptococcus mutans and inhibition of bacterial induced enamel demineralization of propolis, miswak, and chitosan nanoparticles based dental varnishes. J Adv Res. 2017 Jul;8(4):387-392. doi: 10.1016/j.jare.2017.05.006. Epub 2017 May 17.
PubMed 28560054Ibrahim MA, Meera Priyadarshini B, Neo J, Fawzy AS. Characterization of Chitosan/TiO2 Nano-Powder Modified Glass-Ionomer Cement for Restorative Dental Applications. J Esthet Restor Dent. 2017 Apr;29(2):146-156. doi: 10.1111/jerd.12282. Epub 2017 Feb 12.
PubMed 28190299Ibrahim MA, Neo J, Esguerra RJ, Fawzy AS. Characterization of antibacterial and adhesion properties of chitosan-modified glass ionomer cement. J Biomater Appl. 2015 Oct;30(4):409-19. doi: 10.1177/0885328215589672. Epub 2015 Jun 15.
PubMed 26079388Kabil NS, Badran AS, Wassel MO. Effect of the addition of chlorhexidine and miswak extract on the clinical performance and antibacterial properties of conventional glass ionomer: an in vivo study. Int J Paediatr Dent. 2017 Sep;27(5):380-387. doi: 10.1111/ipd.12273. Epub 2016 Oct 21.
PubMed 27766712
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Antimicrobial Activity and Clinical Performance of Chitosan-modified Glass Ionomer: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT04365270
- Acronym / sponsor ID
- FDASU-REC IM 011730
- Conditions
- Reversible Pulpitis, Pulpitis, Caries,Dental, Caries Class I, Caries; Dentin, Caries
- Keywords
- Glass ionomer, Chitosan, Titanium dioxide, Titanium dioxide nanoparticles, Chlorhexidine, indirect pulp capping, Alternative restorative technique, stepwise caries excavation
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 65 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 15 Jan 2019 (actual)
- Primary completion
- 5 Jan 2021 (actual)
- Study completion
- 5 Jan 2021 (actual)
- First posted
- 28 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is a randomized clinical trial that assesses the clinical success and the antibacterial effect on carious dentine of glass ionomer when modified with Chitosan and/or Titanium dioxide nano particles vs the control group of modification with Chlorhexidine as control when used in primary molars
Detailed description
Participants will be recruited from the acquitted to the clinic of pediatric dentistry department , Faculty of Dentistry of Ain Shams University. random allocation of the participants where indirect pulp capping is indicated so that modified Glass ionomer would be used as the filling material.
partial removal of caries is done then caries sample would be taken and sent for a microbiological evaluation and then, cavity dimensions is recoded, finally placement of the modified glass ionomer in the prepared cavity.
In a total period of 9 months the patients will be followed every 3 months for clinical evaluation and in the final visit the filling would be removed and another bacterial sample would be taken for comparison, then a permanent filling is placed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Chitosan Glass ionomer | Experimental | Drug: Glass Ionomer, Drug: Chitosan Low Molecular Weight (20-200 Mpa.S)purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan. will be placed in the prepared cavity over the last layer of caries |
| Chitosan/Titanium dioxide nanoparticles Glass ionomer | Experimental | Drug: Glass Ionomer, Drug: Chitosan Low Molecular Weight (20-200 Mpa.S), Drug: Titanium DioxideThe stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid. The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries |
| Chlorhexidine glass ionomer | Active comparator | Drug: Glass Ionomer, Drug: Chlorhexidine DiacetateChlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v |
| Glass ionomer | Placebo comparator | Drug: Glass IonomerStock powder and liquid Fuji IX from GC japan |
Who may qualify
- Ages
- 4 to 8 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- The teeth will be primary molars selected from patients presented to the outpatient clinic that are
- Healthy patients.
- Age: 4-8 years.
- Children having at least one primary molar with only occlusal caries having dentine lesions wide enough for the smallest excavator to enter (Ø=0.9 mm).
Key exclusion criteria (4 listed)
- Teeth with pulp involvement, those suffering from pain, irreversible pulpits or pulp necrosis.
- Children with systemic diseases.
- Patients with history of active para-functional oral habits, xerostomia.
- Patients who will have difficulties in cooperating.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Glass IonomerAlso: Fuji IXGlass ionomer filling material would be modified accordingly or used as is | Drug | Chitosan Glass ionomer, Chitosan/Titanium dioxide nanoparticles Glass ionomer, Chlorhexidine glass ionomer, Glass ionomer |
| Chitosan Low Molecular Weight (20-200 Mpa.S)Also: Aldrich, cat#448869, lot #STBG9041deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying | Drug | Chitosan Glass ionomer, Chitosan/Titanium dioxide nanoparticles Glass ionomer |
| Chlorhexidine DiacetateAlso: chlorhexidine acetateChlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716 | Drug | Chlorhexidine glass ionomer |
| Titanium DioxideAlso: Titanium(IV) oxideTitanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), >99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332 | Drug | Chitosan/Titanium dioxide nanoparticles Glass ionomer |
Primary outcome
Antibacterial
Time frame: 9 months
Dentin samples incubated on 2 culture mediums and total bacterial count by counting colony forming units will be counted. Higher number means Less antibacterial effect
Clinical performance
Time frame: followup 9 months
"Modified United States Public Health Service Ryge Criteria" for Direct Clinical Evaluation and rating of Restoration.measuring color match, anatomic contour, marginal integrity, cavosurface marginal discoloration, secondary caries, surface texture, gross fracture. each outcome will be graded Alpha(A) for the highest score, Bravo(b) for moderate score, and Charlie(C) for the lowest score.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2021.
- Background: PubMed 31686917Mulder R, Anderson-Small C. Ion release of chitosan and nanodiamond modified glass ionomer restorative cements. Clin Cosmet Investig Dent. 2019 Sep 6;11:313-320. doi: 10.2147/CCIDE.S220089. eCollection 2019.
- Background: PubMed 28560054Wassel MO, Khattab MA. Antibacterial activity against Streptococcus mutans and inhibition of bacterial induced enamel demineralization of propolis, miswak, and chitosan nanoparticles based dental varnishes. J Adv Res. 2017 Jul;8(4):387-392. doi: 10.1016/j.jare.2017.05.006. Epub 2017 May 17.
- Results publication: PubMed 28190299Ibrahim MA, Meera Priyadarshini B, Neo J, Fawzy AS. Characterization of Chitosan/TiO2 Nano-Powder Modified Glass-Ionomer Cement for Restorative Dental Applications. J Esthet Restor Dent. 2017 Apr;29(2):146-156. doi: 10.1111/jerd.12282. Epub 2017 Feb 12.
- Results publication: PubMed 26079388Ibrahim MA, Neo J, Esguerra RJ, Fawzy AS. Characterization of antibacterial and adhesion properties of chitosan-modified glass ionomer cement. J Biomater Appl. 2015 Oct;30(4):409-19. doi: 10.1177/0885328215589672. Epub 2015 Jun 15.
- Results publication: PubMed 27766712Kabil NS, Badran AS, Wassel MO. Effect of the addition of chlorhexidine and miswak extract on the clinical performance and antibacterial properties of conventional glass ionomer: an in vivo study. Int J Paediatr Dent. 2017 Sep;27(5):380-387. doi: 10.1111/ipd.12273. Epub 2016 Oct 21.
- Individual participant dataSharing planned: No
Related trials for Reversible Pulpitis
Not yet recruiting
Effect of Hemostatic Agents on TheraCal PT Pulpotomy Success in Primary Molars
Reversible Pulpitis, Dental Caries
Recruiting
Pomegranate Peel Extract for Primary Molar Pulpotomy
Pulpitis Reversible, Pulp Exposure, Dental
Recruiting
Pelargonium Graveolens Essential Oil as a Pulpotomy Agent in Primary Teeth
Pulpitis - Reversible, Pulpotomies on Primary Molars
Active, not recruiting
Pulp Inflammatory Markers and Outcome of Pulpotomy
Pulpitis in Permanent Teeth, Dental Caries Extending to Pulp
Recruiting
Comparative Evaluation of Direct Pulp Capping Between Deep and Extremely Deep Caries in Mature Permanent Mandibular Molars .
Reversible Pulpitis, Deep Caries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mariem Wassel, Assistant professor study chair
Ainshams University
Noha Kabil, Professor study director
Ainshams university
omar A Hodhod, Dentist principal investigator
British University in cairo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Glass Ionomer, Chitosan Low Molecular Weight (20-200 Mpa.S) and Chlorhexidine Diacetate in people with Reversible Pulpitis and Pulpitis, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antibacterial (time frame: 9 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04365270, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2021.